Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Non-Current Deffered Revenue (2020 - 2022)

MoonLake Immunotherapeutics' Non-Current Deffered Revenue history spans 3 years, with the latest figure at $4.0 million for Q1 2022.

  • Quarterly Non-Current Deffered Revenue changed 0.0% to $4.0 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Mar 2022, changed 0.0% year-over-year, with the annual reading at $4.0 million for FY2021, 0.0% changed from the prior year.
  • Non-Current Deffered Revenue came in at $4.0 million for Q1 2022, roughly flat from $4.0 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $4.0 million in Q4 2020 to a low of $4.0 million in Q4 2020.
  • The 3-year median for Non-Current Deffered Revenue is $4.0 million (2020), against an average of $4.0 million.
  • The largest YoY upside for Non-Current Deffered Revenue was 0.0% in 2021 against a maximum downside of 0.0% in 2021.
  • MoonLake Immunotherapeutics' Non-Current Deffered Revenue stood at $4.0 million in 2020, then changed by 0.0% to $4.0 million in 2021, then changed by 0.0% to $4.0 million in 2022.
  • Per Business Quant, the three most recent readings for MLTX's Non-Current Deffered Revenue are $4.0 million (Q1 2022), $4.0 million (Q4 2021), and $4.0 million (Q3 2021).